BIO-TECHNE Corp Proceeds from Sale of Debt Securities, Available-for-sale
BIO-TECHNE Corp (TECH) reported Proceeds from Sale of Debt Securities, Available-for-sale of $1.08 million for the 12-month period ending 2025-06-30, per its 10-K filed 2026-08-24.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-08-24
- BIO-TECHNE Corp proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- BIO-TECHNE Corp proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-03-31 was $0.00.
- BIO-TECHNE Corp proceeds from sale of debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00.
- BIO-TECHNE Corp proceeds from sale of debt securities, available-for-sale for the quarter ending 2024-09-30 was $1.08M, a 95.43% decline year-over-year.
- BIO-TECHNE Corp proceeds from sale of debt securities, available-for-sale for fiscal 2025 was $1.08M, a 96.14% decline from fiscal 2024.
- BIO-TECHNE Corp proceeds from sale of debt securities, available-for-sale for fiscal 2024 was $28.08M, a 20.30% decline from fiscal 2023.
- BIO-TECHNE Corp proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $35.24M, a 35.24% increase from fiscal 2022.
- BIO-TECHNE Corp proceeds from sale of debt securities, available-for-sale for fiscal 2022 was $26.05M.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $0.00 derived: sum of 2 quarters · filed 2026-08-24 | $0.00 derived: sum of 3 quarters · filed 2026-08-24 | $1.08M 10-K · filed 2026-08-24 |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-06 | $0.00 derived: sum of 2 quarters · filed 2026-05-06 | $1.08M 10-Q · filed 2026-05-06 | $5.41M derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-04 | $1.08M 10-Q · filed 2026-02-04 | $5.41M derived: sum of 3 quarters · filed 2026-08-24 | $5.41M derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-09-30 | $1.08M 10-Q · filed 2025-11-05 | $5.41M derived: sum of 2 quarters · filed 2026-08-24 | $5.41M derived: sum of 3 quarters · filed 2026-08-24 | $5.41M derived: sum of 4 quarters · filed 2026-08-24 |
| 2024-06-30 | $4.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-24 | $4.32M derived: sum of 2 quarters · filed 2026-08-24 | $4.32M derived: sum of 3 quarters · filed 2026-08-24 | $28.08M 10-K · filed 2026-08-24 |
| 2024-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-05-08 | $23.76M 10-Q · filed 2025-05-08 | $29.83M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-06 | $23.76M 10-Q · filed 2025-02-06 | $29.83M derived: sum of 3 quarters · filed 2025-08-22 | $32.49M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-09-30 | $23.76M 10-Q · filed 2024-11-05 | $29.83M derived: sum of 2 quarters · filed 2025-08-22 | $32.49M derived: sum of 3 quarters · filed 2025-08-22 | $44.49M derived: sum of 4 quarters · filed 2025-08-22 |
| 2023-06-30 | $6.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22 | $8.73M derived: sum of 2 quarters · filed 2025-08-22 | $20.73M derived: sum of 3 quarters · filed 2025-08-22 | $35.24M 10-K · filed 2025-08-22 |
| 2023-03-31 | $2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-06 | $14.65M derived: sum of 2 quarters · filed 2024-05-06 | $29.16M 10-Q · filed 2024-05-06 | |
| 2022-12-31 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-07 | $26.51M 10-Q · filed 2024-02-07 | ||
| 2022-09-30 | $14.51M 10-Q · filed 2023-11-07 | |||
| 2022-06-30 | $26.05M 10-K · filed 2024-08-22 | |||
| 2014-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09 | $0.00 10-Q · filed 2015-02-09 | $186.60M derived: sum of 3 quarters · filed 2015-02-09 | $195.63M derived: sum of 4 quarters · filed 2015-05-11 |
| 2014-09-30 | $0.00 10-Q · filed 2014-11-10 | $186.60M derived: sum of 2 quarters · filed 2014-11-10 | $195.63M derived: sum of 3 quarters · filed 2015-05-11 | $217.28M derived: sum of 4 quarters · filed 2015-05-11 |
| 2014-06-30 | $186.60M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $195.63M derived: sum of 2 quarters · filed 2015-05-11 | $217.28M derived: sum of 3 quarters · filed 2015-05-11 | $229.97M 10-K · filed 2014-08-29 |
| 2014-03-31 | $9.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11 | $30.68M derived: sum of 2 quarters · filed 2015-05-11 | $43.38M 10-Q · filed 2015-05-11 | $58.52M derived: sum of 4 quarters · filed 2015-05-11 |
| 2013-12-31 | $21.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09 | $34.34M 10-Q · filed 2015-02-09 | $49.48M derived: sum of 3 quarters · filed 2015-02-09 | $59.31M derived: sum of 4 quarters · filed 2015-02-09 |
| 2013-09-30 | $12.70M 10-Q · filed 2014-11-10 | $27.84M derived: sum of 2 quarters · filed 2014-11-10 | $37.67M derived: sum of 3 quarters · filed 2014-11-10 | $48.01M derived: sum of 4 quarters · filed 2014-11-10 |
| 2013-06-30 | $15.14M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $24.97M derived: sum of 2 quarters · filed 2014-08-29 | $35.31M derived: sum of 3 quarters · filed 2014-08-29 | $41.51M 10-K · filed 2014-08-29 |
| 2013-03-31 | $9.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-12 | $20.17M derived: sum of 2 quarters · filed 2014-05-12 | $26.37M 10-Q · filed 2014-05-12 | $36.73M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-12-31 | $10.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-04 | $16.54M 10-Q · filed 2014-02-04 | $26.90M derived: sum of 3 quarters · filed 2014-08-29 | $41.74M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-09-30 | $6.20M 10-Q · filed 2013-11-12 | $16.56M derived: sum of 2 quarters · filed 2014-08-29 | $31.41M derived: sum of 3 quarters · filed 2014-08-29 | $60.30M derived: sum of 4 quarters · filed 2014-08-29 |
| 2012-06-30 | $10.36M derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-29 | $25.21M derived: sum of 2 quarters · filed 2014-08-29 | $54.10M derived: sum of 3 quarters · filed 2014-08-29 | $64.29M 10-K · filed 2014-08-29 |
| 2012-03-31 | $14.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-10 | $43.74M derived: sum of 2 quarters · filed 2013-05-10 | $53.93M 10-Q · filed 2013-05-10 | $90.31M derived: sum of 4 quarters · filed 2013-08-29 |
| 2011-12-31 | $28.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-11 | $39.09M 10-Q · filed 2013-02-11 | $75.47M derived: sum of 3 quarters · filed 2013-08-29 | $117.76M derived: sum of 4 quarters · filed 2013-08-29 |
| 2011-09-30 | $10.20M 10-Q · filed 2012-11-09 | $46.58M derived: sum of 2 quarters · filed 2013-08-29 | $88.87M derived: sum of 3 quarters · filed 2013-08-29 | $124.91M derived: sum of 4 quarters · filed 2013-08-29 |
| 2011-06-30 | $36.38M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-29 | $78.67M derived: sum of 2 quarters · filed 2013-08-29 | $114.71M derived: sum of 3 quarters · filed 2013-08-29 | $134.02M 10-K · filed 2013-08-29 |
| 2011-03-31 | $42.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-10 | $78.33M derived: sum of 2 quarters · filed 2012-05-10 | $97.64M 10-Q · filed 2012-05-10 | $117.09M derived: sum of 4 quarters · filed 2012-08-29 |
| 2010-12-31 | $36.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-07 | $55.35M 10-Q · filed 2012-02-07 | $74.80M derived: sum of 3 quarters · filed 2012-08-29 | $81.27M derived: sum of 4 quarters · filed 2012-08-29 |
| 2010-09-30 | $19.31M 10-Q · filed 2011-11-09 | $38.76M derived: sum of 2 quarters · filed 2012-08-29 | $45.23M derived: sum of 3 quarters · filed 2012-08-29 | $46.23M derived: sum of 4 quarters · filed 2012-08-29 |
| 2010-06-30 | $19.45M derived: 10-K 12 month − 10-Q 9 month · filed 2012-08-29 | $25.92M derived: sum of 2 quarters · filed 2012-08-29 | $26.92M derived: sum of 3 quarters · filed 2012-08-29 | $27.05M 10-K · filed 2012-08-29 |
| 2010-03-31 | $6.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-05-10 | $7.47M derived: sum of 2 quarters · filed 2011-05-10 | $7.59M 10-Q · filed 2011-05-10 | |
| 2009-12-31 | $998.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-02-09 | $1.12M 10-Q · filed 2011-02-09 | ||
| 2009-09-30 | $124.00K 10-Q · filed 2010-11-09 | |||
| 2009-06-30 | $41.35M 10-K · filed 2011-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |